Full-Time

Manager – Quality Solutions

Quality Solutions, SAP

Posted on 9/17/2025

Deadline 10/1/25
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Chennai, Tamil Nadu, India

In Person

Category
QA & Testing (2)
,
Required Skills
Agile
SAP Products
DevOps
Requirements
  • Bachelor’s degree in computer science or Engineering degree and 5 years of relevant experience
  • 8 years' experience in IT system design and/or delivery, 5+ years in Pharma or business process experience
  • At least 5 years of experience working on SAP Quality Management Module, plus very good knowledge in LIMS interface, IDOCS and integration points with Materials Management, Process Order Execution and Warehouse Management. Experience in S4 Hana will be preferable.
  • Demonstrable experience in software development lifecycles using agile principles and DevOps practices
  • A thorough understanding of system GMP /GDP requirements in detailed knowledge of IT system design and the maintenance lifecycle in GMP environments.
  • Knowledge or familiarity with the production support process, including tasks, escalation routes, communications, and other related activities
  • Proven track record of a successful team lead and solution design.
  • Excellent written and verbal communication skills, with the ability to communicate with business and technical people alike
  • Excellent presentation and facilitation skills, with the ability to interact with various levels of management
  • Excellent organization and problem-solving skills
  • Excellent leadership and project management skills
  • Quick learner. Demonstrate initiative and ownership.
  • Ability to operate in a global multi-cultural environment of time zones and requirements
  • High degree of business process acumen understanding the life cycle of product creation (Plan, Source, Make, Deliver, Return)
Responsibilities
  • Develop and manage project plans, including spend, resourcing and deliverables to design, configure, and develop Quality solutions using technologies such as SAP standard configuration, SAP QM, PP, WM and FIORI
  • Able to Configure, design, development and implementation of Digital projects leveraging enterprise core solutions including but not limited to SAP ECC (modules – MM, PP, QM, WM), SAP S/4.
  • Learn and gain expertise in Pfizer’s Plant network global model template focusing on product quality and batch management. Also learn Pfizer’s Business Processes relevant to these solution areas.
  • Design solutions for Continuous Improvement Enhancement Requests (ERs) that are high quality, reflect the most optimal use of available funding, and are implemented in a way that does not adversely impact Pfizer’s global SAP footprint.
  • Communicate effectively with stakeholders at various locations globally to ensure that they are adequately informed about the status of requests submitted by them and are kept abreast on progress made and issues encountered.
  • Serve as a Project Manager for bigger projects and serve as a coach to the contractors on smaller projects. Take responsibility for the deliverables and ensure cost and timeline commitments made to the business are adhered.
  • Conduct business requirements gathering meetings and workshops in an efficient and productive manner and documents minutes, notes and requirements concisely.
  • Translate business requirements into technical specifications and liaise with technical development teams to develop and implement system solutions to satisfy business needs.
  • Develop cost estimates for projects, create spend forecast and maintain project financial details in Pfizer internal tools and project portfolio systems.
  • Stay abreast of new technology trends and look for ways to apply new technologies where it makes sense.
  • Learn and adopt internal working procedures and foster conformance and standardization. Also suggest ways to improve procedures and practices.
  • Partner closely with other Solutions Teams for cross-functional projects, and with other work streams within the Supply Chain Solutions Team such as TechDev, Integration, Data, Business Adoption, Compliance, BI, Serialization, and Security.
  • Engage with in cross functional teams including key business stakeholders within Pfizer Global Supply (PGS) and Digital colleagues to contribute to the business process and system development life cycle.
  • Provide technical and functional guidance to key stakeholders within PGS
  • Assist in unit, cycle, and integration testing of developed programs including but not limited to SAP PP, QM, WM and SAP Fiori.
  • Ensure compliance to GMP, deployment standards and quality guidelines with regulatory related obligations are executed with the highest standards of compliance.
  • Support testing and other activities necessary for SAP IDOC/File interfaces.
  • Develop ideas and lead complex projects within and across multiple business units / Digital delivery centers.
Desired Qualifications
  • SAP Quality Management and industry experience
  • Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, led by Padcev up 39% and Lorbrena up 32%.
  • VYNDAMAX patent extended to 2031 secures 75% US prescription share in cardiology.
  • ELREXFIO Phase 3 data supports earlier multiple myeloma use against J&J and BMS competitors.

What critics are saying

  • Eliquis patent expiry in 2026 triggers generic entry, eroding $17B peak cardiology sales.
  • Ibrance loses exclusivity in 2027, unleashing generics that destroy $5B breast cancer revenue.
  • Rigel deal forfeits Pfizer's Veppanu royalties, ceding 50-70% of breast cancer peak sales.

What makes Pfizer unique

  • Pfizer pioneered VEPPANU, FDA-approved first PROTAC therapy for ESR1-mutated breast cancer in May 2026.
  • Seagen acquisition doubled Pfizer's ADC trials across bladder, breast, lung, and colorectal cancers.
  • Flatiron Health collaboration since 2014 integrates real-world data for NSCLC and CRC development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE